For decades, the phenomenon of T cell exhaustion in tumors has puzzled immunologists and oncologists alike. Mitochondrial dysfunction has long been acknowledged as a hallmark of exhausted CD8⁺ T cells, yet the precise molecular mechanisms translating metabolic stress into enduring transcriptional reprogramming remained enigmatic. A groundbreaking study led by Professor Ping-Chih Ho and his team at the University of Lausanne has now uncovered a crucial molecular conduit that transforms mitochondrial distress into irreversible immune cell exhaustion, offering transformative insights for cancer immunotherapy.
At the core of this discovery lies the behavior of mitochondria under stress. Upon depolarization—a condition indicating a loss of mitochondrial membrane potential—CD8⁺ T cells ramp up proteasome activity, the cellular machinery responsible for degrading proteins. Intriguingly, this process selectively targets mitochondrial hemoproteins. Their breakdown results in the liberation of regulatory heme, a molecule traditionally considered merely as a metabolic byproduct rather than a signaling entity. This reframing of regulatory heme heralds a paradigm shift in our understanding of intracellular communication pathways governing immune cell fate.
Rather than lingering inertly within the cytoplasm, the freed regulatory heme embarks on a journey to the nucleus of the T cell, where it executes a critical role. Here, heme binds to the transcription factor Bach2, inducing its destabilization. Bach2 normally acts as a repressor of Blimp1, a master regulator of terminal exhaustion in T cells. The degradation of Bach2 effectively lifts this repression, triggering the upregulation of Blimp1. This shift decisively locks T cells into an exhausted, dysfunctional state and erodes their stem-like properties critical for sustained immune responses.
Deciphering this cellular circuitry required delving deep into the molecular players orchestrating these changes. The researchers identified the E3 ubiquitin ligase CBLB as a pivotal driver in tagging mitochondrial proteins for proteasomal degradation. This selective ubiquitination marks hemoproteins for breakdown, fueling the excess heme pool. Meanwhile, PGRMC2 was characterized as the chaperone responsible for escorting regulatory heme into the nucleus, facilitating its interaction with Bach2. Together, these molecules form an elegant metabolic signaling switch bridging mitochondrial status to transcriptional fate decisions.
Professor Ho emphasizes the significance of this discovery: “We uncovered a metabolic signaling switch that converts mitochondrial stress into a permanent transcriptional decision. This pathway explains how energy failure becomes immune failure.” His team has further demonstrated that this molecular axis is not merely descriptive but clinically actionable. Through transient, low-dose administration of the proteasome inhibitor bortezomib during CAR-T cell manufacture, proteasome-driven heme signaling can be attenuated. This intervention downregulates exhaustion-associated gene programs, promoting durable epigenetic reprogramming toward a stem-like, memory phenotype that correlates with enhanced T cell persistence.
The clinical relevance of these findings is underscored by patient data from individuals with B-cell acute lymphoblastic leukemia (B-ALL). CAR-T cells exhibiting elevated proteasome activity were associated with poorer therapeutic outcomes, highlighting the prognostic and potentially therapeutic value of targeting this heme signaling pathway. As first author Y. Xu notes, “Our previous work identified mitochondrial damage as the cause of T cell failure, and this study reveals the molecular switch behind it and how to turn exhaustion off. Identifying regulatory heme as a signaling mediator was unexpected and provides a tangible avenue for intervention.”
Collectively, these discoveries redefine T cell exhaustion not simply as a consequence of chronic antigen exposure but as an active outcome of dysregulated metabolic signaling cascades. The integration of proteostasis, mitochondrial health, and nuclear transcription factor modulation represents a sophisticated cellular strategy regulating immune cell fate under stress conditions. Such insights into fundamental T cell biology are poised to reshape approaches to adoptive cell therapies, including CAR-T cells, where durability and functional persistence remain major clinical challenges.
This study bridges metabolic biology and immuno-oncology, presenting a seamless mechanism whereby proteasome-guided heme signaling irrevocably imprints exhaustion programs onto T cells. Therapeutic modulation of this axis opens new frontiers in optimizing CAR-T cell manufacturing protocols and designing combination therapies to circumvent immune failure. By targeting early molecular events linking energy deprivation to transcriptional reprogramming, future interventions could dramatically enhance the longevity and efficacy of engineered immune cells deployed against cancer.
The international collaborative effort spearheaded by Professor Ho and Y. Xu involved researchers from institutions spanning Switzerland, China, Taiwan, the United Kingdom, and the United States, underscoring the global commitment to unraveling immune dysfunction in cancer. Their work received robust support from prestigious funding agencies including the Swiss National Science Foundation and the Cancer Research Institute. Such multidisciplinary and multinational endeavors exemplify the power of converging expertise to solve complex biomedical puzzles.
In summary, the revelation of regulatory heme as a pivotal signaling molecule in T cell exhaustion heralds a new chapter in understanding how metabolic stress translates into irreversible immune cell fate decisions. This metabolic-transcriptional crosstalk mediated by proteasome activity, CBLB, and PGRMC2 not only elucidates fundamental mechanisms of immune dysfunction but also offers a promising therapeutic switch. Attenuating this pathway could revolutionize adoptive immunotherapies and pave the way toward more durable cancer treatments, finally turning the tide in the battle against T cell exhaustion.
Subject of Research:
T cell exhaustion and metabolic signaling pathways in cancer immunotherapy
Article Title:
Proteasome-guided haem signalling axis contributes to T cell exhaustion
News Publication Date:
18-Mar-2026
Web References:
http://dx.doi.org/10.1038/s41586-026-10250-y
Image Credits:
Ho Lab, 2025
Keywords:
Cancer, T lymphocytes, Mitochondria, Proteasomes, Transcription factors, Immunotherapy, Hemoproteins, Regulatory heme, CAR-T cells, Proteasome activity, Immune exhaustion, Metabolic signaling
Tags: Cancer Immunotherapy ResistanceCD8+ T cell metabolic stressimmune cell transcriptional reprogrammingimmune metabolism and cancer treatmentintracellular heme signaling pathwaysmitochondrial depolarization effectsmitochondrial dysfunction in immune cellsmitochondrial hemoprotein degradationmolecular mechanisms of immune exhaustionproteasome activity in T cellsregulatory heme signalingT cell exhaustion in cancer
